DHR vs TMO vs NTRA
161 measures in 16 categories, one definition each, computed from filings and market data.
DHR65.3
Danaher Corporation
Healthcare · Medical - Diagnostics & Research
$229.04 −1.06%$161.0B mkt cap
Score DNA
TMO62.7
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$690.00 −0.90%$255.1B mkt cap
Score DNA
NTRA50.2
Natera, Inc.
Healthcare · Medical - Diagnostics & Research
$393.44 −2.80%$56.7B mkt cap
Score DNA
Price, rebased to 100 three years ago
DHR TMO NTRA · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 11 | 3 | 0 |
| Last Congress purchase | 2026-06-16 | 2026-08-07 | — |
| 13F net change in holders | −61 | +24 | +85 |
| ETFs adding shares, 30d | 1,288 | 1,408 | 806 |
| ETFs trimming, 30d | 1,089 | 1,184 | 695 |
| Net ETF funds, 30d | +199 | +224 | +111 |
Valuation
16 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| P/E (TTM) | 40.2x
76th
|
36.6x
59th
|
— |
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 4.33
88th
|
— |
| Price / sales | 6.4x
62nd
|
5.5x
48th
|
20.9x
93rd
|
| Price / book | 3.1x
44th
|
4.8x
52nd
|
31.1x
96th
|
| Price / tangible book | — | — | 29.5x
93rd
|
| Price / free cash flow | 29.5x
37th
|
34.9x
53rd
|
791.0x
100th
|
| Price / operating cash flow | 24.3x
43rd
|
28.3x
57th
|
248.5x
100th
|
| Enterprise value | $183.2B
97th
|
$293.6B
100th
|
$55.9B
90th
|
| EV / sales | 7.3x
69th
|
6.3x
55th
|
20.6x
93rd
|
| EV / EBITDA | 25.6x
52nd
|
26.1x
57th
|
— |
| EV / EBIT | 36.3x
71st
|
34.0x
65th
|
— |
| EV / free cash flow | 33.5x
37th
|
40.1x
68th
|
779.1x
100th
|
| Earnings yield | 2.5%
55th
|
2.7%
66th
|
-0.3%
38th
|
| FCF yield | 3.4%
76th
|
2.9%
66th
|
0.1%
34th
|
| Operating cash flow yield | 4.1%
66th
|
3.5%
55th
|
0.4%
21st
|
| Graham number (per share) | $97.27
76th
|
$245.13
100th
|
— |
Profitability (TTM)
12 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Gross margin | 58.5%
62nd
|
41.0%
38th
|
65.3%
76th
|
| EBITDA margin | 28.5%
83rd
|
24.3%
72nd
|
-6.6%
17th
|
| Operating margin | 20.4%
76th
|
17.7%
72nd
|
-10.7%
21st
|
| EBIT margin | 20.1%
76th
|
18.6%
69th
|
-9.0%
21st
|
| Net margin | 15.9%
72nd
|
15.1%
69th
|
-7.1%
24th
|
| NOPAT margin | 17.2%
76th
|
16.3%
69th
|
-8.5%
21st
|
| FCF margin | 21.8%
90th
|
15.8%
62nd
|
2.6%
34th
|
| Operating cash flow margin | 26.4%
86th
|
19.5%
59th
|
8.4%
28th
|
| R&D / revenue | 6.4%
41st
|
3.0%
28th
|
29.1%
90th
|
| SG&A / revenue | 31.7%
52nd
|
17.4%
17th
|
46.4%
69th
|
| Stock comp / revenue | 1.5%
25th
|
0.2%
0th
|
10.7%
86th
|
| Effective tax rate | 15.9%
28th
|
7.8%
10th
|
21.0%
52nd
|
Returns on capital
11 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| ROE (on average equity) | 7.6%
56th
|
13.5%
70th
|
-12.5%
15th
|
| ROA | 4.6%
55th
|
6.5%
72nd
|
-8.7%
17th
|
| ROIC | 5.8%
52nd
|
8.3%
59th
|
-23.6%
10th
|
| ROCE | 6.0%
59th
|
8.8%
66th
|
-11.6%
17th
|
| Return on tangible assets | 5.8%
59th
|
8.1%
72nd
|
-11.1%
17th
|
| Cash ROIC (OCF / invested capital) | 8.9%
34th
|
9.9%
38th
|
23.6%
79th
|
| Gross profitability (GP / assets) | 15.9%
31st
|
16.5%
34th
|
66.5%
93rd
|
| ROIC, 3-yr average | 5.1%
62nd
|
8.3%
83rd
|
-85.7%
0th
|
| ROIC, 5-yr average | 7.4%
67th
|
9.8%
83rd
|
73.5%
100th
|
| ROE, 5-yr average | 9.7%
64th
|
14.0%
76th
|
-56.2%
4th
|
| Incremental ROIC | 17.5%
63rd
|
15.6%
59th
|
-4.7%
48th
|
Growth
17 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.6%
25th
|
7.2%
46th
|
37.8%
93rd
|
| Revenue growth (QoQ) | 5.3%
31st
|
9.0%
66th
|
8.1%
48th
|
| Revenue CAGR, 3 yr | -3.5%
7th
|
2.1%
41st
|
42.7%
100th
|
| Revenue CAGR, 5 yr | -1.2%
19th
|
3.9%
41st
|
39.9%
100th
|
| Gross profit CAGR, 3 yr | -3.8%
22nd
|
3.4%
37th
|
64.7%
96th
|
| Operating income CAGR, 3 yr | -9.7%
13th
|
4.3%
40th
|
— |
| Net income growth (TTM YoY) | 17.3%
62nd
|
6.0%
25th
|
— |
| Net income CAGR, 3 yr | -14.3%
17th
|
6.8%
58th
|
— |
| EPS growth (TTM YoY) | 19.2%
69th
|
8.0%
25th
|
— |
| EPS CAGR, 3 yr | -12.8%
17th
|
8.5%
42nd
|
— |
| EPS CAGR, 5 yr | -5.8%
36th
|
-2.8%
43rd
|
— |
| FCF growth (TTM YoY) | 12.4%
50th
|
18.6%
61st
|
-31.4%
11th
|
| FCF CAGR, 3 yr | -8.8%
0th
|
7.7%
50th
|
— |
| Operating cash flow CAGR, 3 yr | -7.6%
0th
|
5.4%
41st
|
— |
| Book value CAGR, 3 yr | 2.3%
48th
|
8.0%
76th
|
34.3%
96th
|
| Dividend CAGR, 3 yr | 7.6%
100th
|
4.3%
80th
|
— |
| Sustainable growth rate | 5.8%
19th
|
12.2%
56th
|
— |
Margin history & stability
7 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Gross margin, 3-yr average | 59.8%
68th
|
39.9%
39th
|
60.7%
71st
|
| Operating margin, 3-yr average | 21.2%
86th
|
17.9%
75th
|
-16.2%
25th
|
| Net margin, 3-yr average | 16.0%
86th
|
15.0%
79th
|
-13.8%
25th
|
| FCF margin, 3-yr average | 21.2%
86th
|
16.3%
71st
|
0.0%
29th
|
| Revenue stability (0-1) | 0.35
14th
|
0.82
54th
|
0.93
71st
|
| Earnings stability (0-1) | 0.63
71st
|
0.29
36th
|
0.40
46th
|
| Margin stability (0-1) | 0.98
89th
|
0.88
32nd
|
0.83
14th
|
Liquidity (latest quarter)
7 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Cash & short-term investments | $4.3B
100th
|
$4.1B
97th
|
$1.1B
83rd
|
| Net cash (− = net debt) | −$22.2B
3rd
|
−$38.5B
0th
|
$853.0M
100th
|
| Working capital | $5.3B
97th
|
$8.3B
100th
|
$1.1B
79th
|
| Current ratio | 1.65
31st
|
1.55
24th
|
3.00
62nd
|
| Quick ratio | 1.25
24th
|
1.18
21st
|
2.85
62nd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.54
34th
|
0.27
24th
|
1.97
69th
|
| Defensive interval (days) | 317 days
21st
|
469 days
52nd
|
268 days
14th
|
Leverage & solvency (latest quarter)
13 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Total debt | $26.6B
97th
|
$42.5B
100th
|
$238.5M
34th
|
| Debt / equity | 0.51
52nd
|
0.81
78th
|
0.13
19th
|
| Net debt / equity | 0.42
67th
|
0.73
78th
|
−0.47
19th
|
| Debt / assets | 28.8%
52nd
|
37.6%
72nd
|
9.0%
21st
|
| Debt / capital | 33.6%
50th
|
44.7%
75th
|
11.6%
18th
|
| Debt / EBITDA | 3.71
57th
|
3.78
62nd
|
— |
| Net debt / EBITDA | 3.11
67th
|
3.42
71st
|
— |
| Interest coverage (EBIT / interest) | 64.8x
96th
|
5.9x
64th
|
−24.5x
20th
|
| Cash interest coverage | 85.1x
92nd
|
6.1x
44th
|
22.9x
84th
|
| Debt payback (years of OCF) | 4.0 yrs
52nd
|
4.7 yrs
65th
|
1.0 yrs
22nd
|
| Liabilities / assets | 43.1%
48th
|
53.4%
66th
|
31.5%
24th
|
| IS credit model rating | A+ | A- | A |
| Implied credit spread (bps) | 125
31st
|
175
45th
|
150
34th
|
Efficiency
11 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Asset turnover | 0.29
14th
|
0.43
38th
|
1.23
93rd
|
| Fixed asset turnover | 3.57
34th
|
4.31
48th
|
6.05
83rd
|
| Inventory turnover | 3.5
16th
|
4.9
40th
|
14.0
84th
|
| Receivables turnover | 6.7
55th
|
4.8
21st
|
7.4
76th
|
| Days sales outstanding | 55 days
45th
|
77 days
79th
|
49 days
24th
|
| Days inventory outstanding | 104 days
84th
|
74 days
60th
|
26 days
16th
|
| Days payables outstanding | 62 days
86th
|
41 days
45th
|
22 days
17th
|
| Cash conversion cycle (days) | 97 days
66th
|
109 days
79th
|
54 days
31st
|
| Capex / revenue | 4.7%
62nd
|
3.7%
55th
|
5.8%
76th
|
| Capex / depreciation | 0.56
31st
|
0.64
45th
|
2.39
97th
|
| Operating expense ratio | 39.6%
45th
|
23.8%
24th
|
74.5%
79th
|
Cash flow & earnings quality
7 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Operating cash flow / net income | 1.66
65th
|
1.29
29th
|
— |
| FCF / net income | 1.37
65th
|
1.05
29th
|
— |
| FCF / operating cash flow | 82.4%
57th
|
81.2%
52nd
|
31.4%
17th
|
| Capex / operating cash flow | 17.6%
43rd
|
18.8%
48th
|
68.6%
83rd
|
| Accruals ratio | -3.0%
72nd
|
-1.9%
83rd
|
-19.1%
0th
|
| Sloan accruals ratio | -1.2%
52nd
|
-5.8%
21st
|
-0.3%
55th
|
| Earnings quality score (0-1) | 1.00
24th
|
1.00
24th
|
— |
Scores & forensic checks
15 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| IS score | 65
79th
|
63
76th
|
50
48th
|
| IS profitability | 50
66th
|
52
69th
|
19
31st
|
| IS growth | 54
43rd
|
49
36th
|
87
96th
|
| IS value | 46
69th
|
49
79th
|
32
17th
|
| IS momentum | 83
79th
|
78
61st
|
79
64th
|
| IS risk (safety) | 80
38th
|
80
38th
|
100
62nd
|
| IS quality | 75
69th
|
75
72nd
|
50
38th
|
| IS balance sheet | 60
66th
|
49
45th
|
36
28th
|
| IS earnings quality | 78
97th
|
76
86th
|
29
0th
|
| IS cash flow | 70
76th
|
64
69th
|
23
17th
|
| Piotroski F-score (0-9) | 6
41st
|
7
59th
|
6
41st
|
| Altman Z-score | 3.3
45th
|
3.4
48th
|
27.6
97th
|
| Beneish M-score | −2.57
61st
|
−2.59
54th
|
0.43
100th
|
| Ohlson O-score | −9.48
14th
|
−8.95
21st
|
−8.94
24th
|
| IS credit score | 79
69th
|
69
55th
|
72
66th
|
Size (TTM)
8 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| Market cap | $161.0B
97th
|
$255.1B
100th
|
$56.7B
93rd
|
| Revenue | $25.1B
97th
|
$46.3B
100th
|
$2.7B
52nd
|
| EBITDA | $7.2B
97th
|
$11.3B
100th
|
−$179.1M
7th
|
| Net income | $4.0B
97th
|
$7.0B
100th
|
−$192.3M
10th
|
| Free cash flow | $5.5B
97th
|
$7.3B
100th
|
$71.7M
38th
|
| Total assets | $92.4B
97th
|
$113.2B
100th
|
$2.7B
41st
|
| Shareholders' equity | $52.6B
97th
|
$52.7B
100th
|
$1.8B
55th
|
| Employees | 59,000
90th
|
125,000
100th
|
6,138
48th
|
Price performance
9 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| 1 day | −1.1% | −0.9% | −2.8% |
| 1 week | +4.2% | +4.9% | −1.8% |
| 1 month | +8.0% | +4.8% | +7.4% |
| 3 months | +14.1% | +31.2% | +49.8% |
| 6 months | +18.1% | +31.1% | +88.8% |
| Year to date | 0.0% | +16.5% | +71.9% |
| 1 year | +11.9% | +30.9% | +119.3% |
| 3 years, cumulative | +7.7% | +41.1% | +778.0% |
| 5 years, cumulative | −11.6% | +19.6% | +244.9% |
Technicals
4 measures| Measure | DHR | TMO | NTRA |
|---|---|---|---|
| RSI 14 | 62.7 | 64.1 | 54.9 |
| From 52-week high | −5.1% | −2.0% | −10.1% |
| From 52-week low | +42.9% | +58.6% | +121.0% |
| Beta | 0.80 | 0.88 | 1.50 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17